Cytovation
↗Bergen, Norway
Cytovation is a clinical-stage immunotherapy biotech company founded and headquartered in Bergen, Norway, with research spanning over 15 years. The company specializes in precision oncology, developing first-in-class synthetic peptide immunotherapies that selectively target tumor cell membranes and inhibit the Wnt/β-catenin signaling pathway. Cytovation's unique approach combines tumor membrane lysis with in situ vaccination and immune activation, positioning the company at the forefront of immuno-oncology innovation. The company was spun out from the University of Bergen and has strategic collaborations with leading pharma partners including Merck (MSD) and Cancer Research UK.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2001
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$34M
Investors:Sandwater, Canica, University of Bergen, Haukeland University Hospital
PIPELINE
Stage:Phase I/II - Phase II
Lead Drug Stage:Phase I/IIa (CyPep-1/CY-101)
Modalities:Synthetic peptide, Immunotherapy, mAb combination
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck (MSD) - clinical collaboration evaluating CyPep-1 combination with Keytruda in HNSCC, melanoma, TNBC, Cancer Research UK - Phase 2 sponsor for ACC trial with Norwegian Cancer Society, Norwegian Cancer Society - partnership supporting ACC clinical trial, University of Bergen - founding research institution
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Lars Prestegarden - Chief Executive Officer & Co-founder
Cesar Pico - Head of Clinical Development
Vetle Veiteberg - Deputy Chief Financial Officer
Federico - Chief Operating Officer & Chief Financial Officer
Scientific Founders:Lars Prestegarden
Board Members:Stein Christian Mohn (Board Chair), Øyvind Kongstun Arnesen (Board Member (representing Canica)), Kjell Bernstrøm (Board Member (representing Innovest/University of Bergen)), Hilde Hukkelberg (Independent Board Member), Olav Hellebø (Board Advisor - Clinical Development), Martin Dewhurst (Board Member)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cytovation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cytovation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.